Item 2.02 - Results of Operations and Financial Condition: The filing reports results of operations and financial condition for Waters Corporation as of August 4, 2026 Item 9.01 - Financial Statements and Exhibits: The filing includes financial statements and exhibits related to the reported results Company Information: Waters Corporation, a Delaware-incorporated laboratory analytical instruments…

Our analysis rates this filing NEUTRAL. Waters presents a MODERATE concern profile with a NEUTRAL net assessment. The company is executing well operationally—beating quarterly guidance, raising full-year guidance across all metrics, and demonstrating strong organic growth acceleration (9% constant…

Concern level: ELEVATED (4.2/10). Key factors: Integration Risk from Major Acquisition (Severity 6/10): ~$817M quarterly revenue from BD acquisition introduces material execution complexity; historical allocated costs may not be representative of future standalone costs, creating earnings quality uncertainty; Acquired Business Cost Allocation Uncertainty (Severity 5/10): BD's shared services…

Notable risk changes: POSITIVE: Company raised ALL components of 2026 guidance - organic revenue growth (7-9%), acquired business revenue ($3.045B), and adjusted EPS ($14.45-$14.65 representing 10-12% growth). This reflects better-than-expected Q2 results and strengthening end-market conditions across previously lagging customer segments.; POSITIVE: Organic revenue growth accelerated to 9% in constant currency (vs.…

Total revenue surpassed high end of guidance range; Biosciences and Diagnostic Solutions revenue exceeded guidance by $15 million.

The model predicts WAT will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.